CN107812032A - Application of the beans taro leaf ethanol extract in liver cell lipidosis is reduced - Google Patents
Application of the beans taro leaf ethanol extract in liver cell lipidosis is reduced Download PDFInfo
- Publication number
- CN107812032A CN107812032A CN201711177284.1A CN201711177284A CN107812032A CN 107812032 A CN107812032 A CN 107812032A CN 201711177284 A CN201711177284 A CN 201711177284A CN 107812032 A CN107812032 A CN 107812032A
- Authority
- CN
- China
- Prior art keywords
- beans taro
- ethanol extract
- taro leaf
- eluent
- leaf ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000205754 Colocasia esculenta Species 0.000 title claims abstract description 95
- 235000006481 Colocasia esculenta Nutrition 0.000 title claims abstract description 95
- 244000046052 Phaseolus vulgaris Species 0.000 title claims abstract description 93
- 235000010627 Phaseolus vulgaris Nutrition 0.000 title claims abstract description 93
- 239000000469 ethanolic extract Substances 0.000 title claims abstract description 71
- 210000005229 liver cell Anatomy 0.000 title claims abstract description 18
- 208000000501 Lipidoses Diseases 0.000 title claims abstract description 16
- 206010024585 Lipidosis Diseases 0.000 title claims abstract description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 69
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims abstract description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000003480 eluent Substances 0.000 claims abstract description 30
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000019253 formic acid Nutrition 0.000 claims abstract description 21
- 239000007864 aqueous solution Substances 0.000 claims abstract description 18
- 239000011347 resin Substances 0.000 claims abstract description 17
- 229920005989 resin Polymers 0.000 claims abstract description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000005119 centrifugation Methods 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 12
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 12
- 238000002390 rotary evaporation Methods 0.000 claims abstract description 12
- 239000006228 supernatant Substances 0.000 claims abstract description 12
- 239000012141 concentrate Substances 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 235000013402 health food Nutrition 0.000 claims abstract description 7
- 238000002137 ultrasound extraction Methods 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract 2
- 239000007788 liquid Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- SVWLIIFHXFGESG-UHFFFAOYSA-N formic acid;methanol Chemical compound OC.OC=O SVWLIIFHXFGESG-UHFFFAOYSA-N 0.000 claims 1
- 238000005360 mashing Methods 0.000 abstract description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 47
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 47
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 47
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 47
- 239000005642 Oleic acid Substances 0.000 description 47
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 47
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 26
- 238000011282 treatment Methods 0.000 description 20
- 230000003834 intracellular effect Effects 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 208000004930 Fatty Liver Diseases 0.000 description 10
- 206010019708 Hepatic steatosis Diseases 0.000 description 10
- 208000010706 fatty liver disease Diseases 0.000 description 10
- 231100000240 steatosis hepatitis Toxicity 0.000 description 10
- 150000003626 triacylglycerols Chemical class 0.000 description 10
- 230000006698 induction Effects 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000000151 deposition Methods 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000006481 glucose medium Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000002249 Diabetes Complications Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010012655 Diabetic complications Diseases 0.000 description 3
- 229920002752 Konjac Polymers 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 3
- 229960000516 bezafibrate Drugs 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 2
- 241000931705 Cicada Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- 238000009777 vacuum freeze-drying Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 244000176051 Apios tuberosa Species 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000522190 Desmodium Species 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 244000100170 Phaseolus lunatus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- SYXUBXTYGFJFEH-UHFFFAOYSA-N oat triterpenoid saponin Chemical compound CNC1=CC=CC=C1C(=O)OC1C(C=O)(C)CC2C3(C(O3)CC3C4(CCC5C(C)(CO)C(OC6C(C(O)C(OC7C(C(O)C(O)C(CO)O7)O)CO6)OC6C(C(O)C(O)C(CO)O6)O)CCC53C)C)C4(C)CC(O)C2(C)C1 SYXUBXTYGFJFEH-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of application of beans taro leaf ethanol extract in liver cell lipidosis is reduced：Medicine, the health food of NASH are treated or prevented for preparing.The preparation method of the beans taro leaf ethanol extract comprises the following steps：Mashing, ultrasound extraction, centrifugation, obtain supernatant after 85% ethanol of beans taro leaf and the hydrochloric acid containing 0.1mol/L is mixed；Supernatant is subjected to rotary evaporation concentration in Rotary Evaporators；Concentrate is isolated and purified using macroreticular resin, and the methanol aqueous solution to contain 0.05% formic acid is used as eluant, eluent；Eluent rotary evaporation is concentrated, and then the pulpous state concentrate elder generation pre-freeze of gained is dried into powdered with vacuum freeze drier, obtain beans taro leaf ethanol extract.
Description
Technical field
The present invention relates to field of medicaments, and in particular to the preparation of beans taro leaf ethanol extract and its prepare prevent and treat
Application in NASH health food and medicine；Being related to simultaneously reduces the HepG2 cytolipins deposition of oleic acid induction
Application in NASH is prevented and treated.
Background technology
Beans taro (Apios americana Medikus) originates in the Canadian to Fla. of eastern North America
Southern areas, belong to perennial legume (Papilionaceae subfamily).Its edible portion is underground stem tuber, and its protein contains
Amount is higher than other plant stem tuber, is a kind of not only nutrition but also has the crop of economic value, thus often by American Indian as staple food.Beans
Taro was from domestic successful introduction in 2009, and by gradually in the ground such as Fuyang, Jinhua, Long You, Wenzhou popularizing planting.Research shows beans taro
Different parts (flower, rattan, leaf, stem tuber) are containing abundant free amino acid, soluble protein, polysaccharide, saponin(e, flavones, different Huang
Ketone, vitamin C, vitamin E and mineral matter and other components.Wherein, the Vitamin C content highest of beans taro leaf, while also containing higher
Vitamin E, total saposins and the isoflavones of content, there is great potentiality to be exploited.
U.S. beans taro has obvious improvement to lifestyle-related diseases such as hypertension, diabetes and hyperlipemias.
With the rapid development of modern social economy, the living standard of the people significantly improves, fat (obesity) and its simultaneously
The morbidity and mortality of hair disease are in the trend risen year by year, and in general fatty liver can occur along with obesity.Defended according to the world
Raw in March, 2011 report that is organized in shows, the whole world in 2008 has more than 1,500,000,000 adults and is in overweight level, wherein at least 500,000,000
Fat and fatty liver or.The year two thousand thirty is expected, there will be fat and fatty liver problem for the population in the U.S. 42%.U.S. will be exceeded
The present population 30,000,000 of state.Medical treatment cost increase related to this will reach nearly 550,000,000,000 dollars.And delivered at home according to 2010
Research report claim, China is fat at present and fatty liver population exceedes the U.S., Britain and Australia up to 3.25 hundred million people, amplification,
This numeral will be also possible to double for 20 years in future.Fatty liver and obesity caused by common complication have hypertension, diabetes,
Coronary heart disease, cerebral apoplexy etc..As can be seen here, fat and fatty liver has turned into the universal health problem in the whole world, and prevention and treatment are fat
Disease, fatty liver have become the primary health problem of 21 century.
The means of current prevention and treatment fatty liver mainly include：(1) total heat energy intake is controlled；(2) the method for movement；(3) perform the operation
Therapy；(4) medicinal treatment；(5) non-drug therapy：Acupuncture therapy, Use of Auricular, acupuncture and moxibustion treatment, pointer method of weight-reducing, massage
Method.Wherein using drug therapy as main effective treatment means.The numerous fat-reducing medicaments clinically applied at present all have substantially
Cardiovascular system in terms of side effect.So far, the mankind do not develop a kind of well-content Weight-reducing and lipid-lowering medicine also.
Also the shortcomings of reducing immunity of organisms, easily rebounding mostly be present in other Weight-reducing and lipid-lowering methods.The obesity more serious in face of the whole world
The rise of disease and fatty liver and its incidence of disease by caused metabolic disease, seeks safe and effective new prevention and treatment
Strategy is extremely important.
《U.S.'s beans taro different parts biochemical character constituent analysis》One proclamation cicada：
When measuring free amino acid, soluble protein and total reducing sugar：0.42mm sieves are crossed after crushing, using 3:500 (m/v) are added
100 DEG C of distilled water, water bath with thermostatic control extraction is carried out in 100 DEG C.
When measuring total saposins, general flavone and isoflavone content：Using 1:100 (m/v) add absolute ethyl alcohol, in 60 DEG C of constant temperature
Water-bath 3h.
When measuring VC：Sample 1g is taken, 60 DEG C of ultrasonic 40min are soaked in 40ml 0.01mol/L HCL.
When measuring VE, sample 3g is taken, with addition 20ml absolute ethyl alcohols, 50 DEG C of isothermal vibration 50min.
CN201210574017.9 invention《Method that beans taro flower total saponine, polysaccharide are prepared simultaneously big more and application thereof》Accuse
Cicada herein below：Preparation method is according to the following steps：1) beans taro is got over greatly in harvesting, cleaning, dry, pulverize, and is crossed 40 mesh sieves, is obtained
More beans taro pollen is last greatly；2) more beans taro pollen is last greatly, according to solid-liquid ratio 1:10~1:20, addition concentration is 70%~90% second
Alcohol, in 50~80 DEG C of refluxing extractions 1~3 time, each 1~3 hour time, filtering, obtain supernatant and filter residue；3) supernatant, wave
Dissolved after dry with water, petroleum ether degreasing, extracting n-butyl alcohol, take n-butanol fraction after macroporous absorbent resin absorb-elute, concentrated,
It is dried to obtain beans taro saponin(e powder；4) filter residue, solvent is volatilized, with 10~20 times of distilled water of its weight, is flowed back in 70~90 DEG C
Extraction 1~3 time, each 2~3 hours time, filtering, collect and merge filtered solution；5) filtered solution decolourizes, takes off albumen, concentrates, and adds
Ethanol, stands overnight carry out alcohol precipitation, collects precipitation, after dialysis, with DEAE~cellulose chromatography, and respectively with distilled water, 0.1M,
0.3M, 0.5M~NaCl solution eluent, 0.3M~0.5M~NaCl eluents are collected, dialysed, concentrated, dried, obtain beans taro
Polysaccharide.The total saposins and polysaccharide that the present invention is prepared simultaneously from big more beans taro, purity is high, and activity is strong, can prepare
It is used widely in the medicine or functional food that are acted on anti-oxidant, blood glucose-control.
201310414063.7《A kind of konjaku polypeptide extract, preparation method and its usage》Inform herein below：
Fry starch of konjak addition pure water regulation pH value to 9.0 is extracted, then by 2 enzyme digestion reactions, then through ultrafiltration purification, obtained magic
Taro polypeptide.The konjaku polypeptide can be used to treat diabetes and diabetic complication, and diabetic complication includes diabetic complication
Atherosclerosis, diabetic retinopathy, NASH and diabetic nephropathy etc..
The content of the invention
The technical problem to be solved in the present invention is to provide the beans taro leaf ethanol extract that a kind of ad hoc approach is prepared to exist
Prepare the application in prevention and treatment NASH health food and medicine；Being related to simultaneously reduces oleic acid induction
HepG2 cytolipins are deposited on the application in preventing and treating NASH.
In order to solve the above-mentioned technical problem, the present invention provides a kind of beans taro leaf ethanol extract and sunk in reduction liver cell lipid
In product
The improvement of application of the beans taro leaf ethanol extract in liver cell lipidosis is reduced as the present invention：For making
Standby medicine, the health food for treating or preventing NASH.
The further improvement of application of the beans taro leaf ethanol extract in liver cell lipidosis is reduced as the present invention：
The preparation method of beans taro leaf ethanol extract is to comprise the following steps：
1), according to 1g:5~10ml (preferably 1g:Solid-liquid ratio 8ml) is by the 85% of beans taro leaf and the hydrochloric acid containing 0.1mol/L
Ethanol mixing after be beaten, gained slurries in 45 ± 5 DEG C ultrasound extraction 240 ± 10min after, extract solution centrifugation (4000 turns/min from
Heart 30min), obtain supernatant；
2) supernatant, is subjected to rotary evaporation concentration until being the 5~10% of original volume in Rotary Evaporators；
3), the concentrate obtained by step 2) is isolated and purified using macroreticular resin；It is water-soluble with the formic acid of volumetric concentration 1%
For liquid as eluent, the methanol aqueous solution to contain 0.05% formic acid collects eluent as eluant, eluent；
The preparation method of the methanol aqueous solution containing 0.05% formic acid is：In the methanol-water of 100ml volumetric concentrations 90%
0.05ml formic acid is added in solution；
4) the eluent rotary evaporation obtained by step 3), is condensed into the 5~10% of most original volume, obtains pulpous state concentration
Liquid；
5), by prior to -70~-90 DEG C 5~7h of pre-freeze of the pulpous state concentrate obtained by step 4), vacuum freeze drying is then used
Machine is dried into powdered, obtains beans taro leaf ethanol extract.
The further improvement of application of the beans taro leaf ethanol extract in liver cell lipidosis is reduced as the present invention：
Step 3) is：
Macroreticular resin is activated with the methanol of twice of column volume first, the distilled water of three times column volume is balanced；Then with
0.4~0.6mL/min (preferably 0.5mL/min) flow velocity loading, after liquid to be extracted is fully adsorbed, with volumetric concentration 1%
Aqueous formic acid is eluted (purpose of elution is to remove the materials such as protein, sugar, acid), the elution as eluent
The dosage of agent is twice of column volume, and flow velocity is 0.4~0.6mL/min (preferably 0.5mL/min)；Finally use and contain 0.05% first
The methanol aqueous solution of acid is eluted as eluant, eluent, and the dosage three times column volume of the eluant, eluent, flow velocity is 0.4~0.6mL/
Min (preferably 0.5mL/min)；Collect eluent.
The further improvement of application of the beans taro leaf ethanol extract in liver cell lipidosis is reduced as the present invention：
Macroreticular resin in the step 3) is macroreticular resin AB-8 (Tianjin Xing Nanyun energy Polymer Technologies Co., Ltd).
The further improvement of application of the beans taro leaf ethanol extract in liver cell lipidosis is reduced as the present invention：
By the filter residue alternative steps 1 of step 1) centrifugation gained) in beans taro leaf repeat being beaten of step 1), ultrasound extraction and from
The heart；Number of repetition is 2~3；
Step 2) is carried out after supernatant obtained by all centrifugations is merged.
In the present invention：
The rotary evaporation of step 2) and step 4) is carried out under 38 ± 2 DEG C, -0.09MPa vacuum.
The vacuum freeze drying of step 5) is carries out under -40 ± 2 DEG C, 1.2Pa vacuum, until the beans taro leaf of gained
Ethanol extract moisture content≤0.1%.
The present invention is tested using HepG2 cells (human liver cancer cell), and beans taro leaf second is determined by tetrazolium bromide (MTT) method
Influence of the alcohol extracting thing processing to HepG2 cell-proliferation activities, and using oleic acid (OA) induction 24h structure cytolipin deposition moulds
Type be subject to simultaneously beans taro leaf ethanol extract intervene 24h, by oil red O stain, measure HepG2 intracellular triglycerides (TC),
T-CHOL (TG) content further verifies that beans taro leaf ethanol extract lowering fat and protecting liver acts on.As a result show, beans taro leaf ethanol carries
Take thing to significantly reduce HepG2 intracellular triglycerides (TC), T-CHOL (TG) content, alleviate the HepG2 of oleic acid induction
Cytolipin deposits.
The HepG2 cytolipins that the present invention is carried out on inducing oleic acid (OA) with beans taro leaf ethanol extract, which deposit, to be alleviated
The experimental study of effect, illustrate that it can be used to prepare prevention and treatment NASH health food and medicine.
The invention discloses application of the beans taro leaf ethanol extract in NASH is treated or prevented, and expands
The application field of beans taro leaf.The beans taro leaf ethanol extract can reduce the HepG2 cytolipins deposition of oleic acid induction, can prepare
Prevent and treat NASH health food and medicine.The beans taro leaf ethanol extract of the present invention can be developed into natural
NASH medicine and food are treated and prevented, instead of artificial synthesized drug therapy disease.
The usage of the beans taro leaf ethanol extract of the present invention is oral, about 150~250mg every time, three times a day.
The present invention compared with the existing technology, has following technical advantage：
1. present invention firstly discovers that the HepG2 cytolipins that beans taro leaf ethanol extract can effectively reduce oleic acid induction sink
Product, has good DEVELOPMENT PROSPECT.
2. the present invention provides new medical application for beans taro leaf ethanol extract, a new application field has been expanded.
Brief description of the drawings
The embodiment of the present invention is described in further detail below in conjunction with the accompanying drawings.
Fig. 1 is that cell viability compares figure after various concentrations beans taro leaf ethanol extract acts on HepG2 cells 24h.
Fig. 2 is that various concentrations beans taro leaf ethanol extract acts on the intracellular fat drips of HepG2 induced after 24h oleic acid (OA)
Influence comparison diagram (100 μm).
A represents control group (DMEM high glucose medium cellar cultures cell)；
B representative models group (oleic acid final concentration 0.5mM)；
C represents positive controls (oleic acid final concentration 0.5mM+10uM Bezafibrates)；
D represents low concentration beans taro leaf ethanol extract treatment group (oleic acid final concentration 0.5mM+ final concentration 100ug/mL beans taros
Leaf ethanol extract)；
Concentration beans taro leaf ethanol extract treatment group (oleic acid final concentration 0.5mM+ final concentration 200ug/mL beans taros during e is represented
Leaf ethanol extract)；
F represents high concentration beans taro leaf ethanol extract treatment group (oleic acid final concentration 0.5mM+ final concentration 300ug/mL beans taros
Leaf ethanol extract).
The HepG2 that Fig. 3 is induced oleic acid (OA) after being various concentrations beans taro leaf ethanol extract effect 24h is fatty into the cell
The influence comparison diagram of deposition.
Fig. 4 is that various concentrations beans taro leaf ethanol extract acts on the HepG2 intracellulars induced after 24h oleic acid (OA)
The influence comparison diagram of three esters (TG) content.
Fig. 5 is that various concentrations beans taro leaf ethanol extract acts on the HepG2 induced after 24h oleic acid (OA) total courages into the cell
The influence comparison diagram of sterol (TC) content.
In Fig. 3~Fig. 5：
C represents control group (DMEM high glucose medium cellar cultures cell)；
OA representative models group (oleic acid final concentration 0.5mM)；
B represents positive controls (oleic acid final concentration 0.5mM+10uM Bezafibrates)；
L represents low concentration beans taro leaf ethanol extract treatment group (oleic acid final concentration 0.5mM+ final concentration 100ug/mL beans taros
Leaf ethanol extract)；
Concentration beans taro leaf ethanol extract treatment group (oleic acid final concentration 0.5mM+ final concentration 200ug/mL beans taros during M is represented
Leaf ethanol extract)；
H represents high concentration beans taro leaf ethanol extract treatment group (oleic acid final concentration 0.5mM+ final concentration 300ug/mL beans taros
Leaf ethanol extract).
Embodiment
With reference to specific embodiment, the present invention is described further, but protection scope of the present invention is not limited in
This：
Embodiment 1, a kind of preparation method of beans taro leaf ethanol extract, are followed the steps below successively：
1), with 1g:8ml ratio mixes 85% ethanol of beans taro leaf and the hydrochloric acid containing 0.1mol/L, is entered using juice extractor
Row mashing；Gained slurries are under the conditions of 45 DEG C, after ultrasonic (40,000Hz ultrasonic frequencies) extraction 240min, extract solution 4000
Turn/min centrifugation 30min,
The beans taro leaf that the filter residue of centrifugation gained is substituted in above-mentioned steps repeat being beaten of above-mentioned steps, ultrasound extraction and
Centrifugation；Number of repetition is 3 times；
Following step 2 is carried out after the supernatant of above-mentioned 3 times centrifugation gained is merged).
2), by the supernatant of gained, in Rotary Evaporators, (technological parameter that rotary evaporation is set is 38 DEG C of temperature, vacuum
Degree -0.09MPa) rotary evaporation concentration is carried out until being the 10% of original volume；
3), revolving gained concentrate is isolated and purified using macroreticular resin, used macroreticular resin is macropore tree
Fat AB-8 (Tianjin Xing Nanyun energy Polymer Technologies Co., Ltd), is followed the steps below successively：
Macroreticular resin is activated with the methanol of twice of column volume first, three times column volume distilled water is balanced；
Then with 0.5mL/min flow velocity loading, applied sample amount is 200ml (for the 10% of column volume)；Extract solution is fully inhaled
Attached, 1% formic acid (that is, the aqueous formic acid of volumetric concentration 1%) elution removes the materials such as protein, sugar, acid, the use of the eluent
Measure as twice of column volume, flow velocity 0.5mL/min；It is finally abundant as eluant, eluent by the use of the methanol aqueous solution for containing 0.05% formic acid
Elution, the dosage three times column volume of the eluant, eluent, flow velocity 0.5mL/min；Collect eluent.
The preparation method of the methanol aqueous solution containing 0.05% formic acid is：In the methanol-water of 100ml volumetric concentrations 90%
0.05ml formic acid is added in solution；
4), macroreticular resin is isolated and purified into gained eluent rotary evaporation (technological parameter that rotary evaporation is set is temperature
38 DEG C, vacuum -0.09MPa) rotary evaporation concentration is carried out until being the 10% of original volume, obtain pulpous state concentrate；
5), by concentrate in -80 DEG C of pre-freeze 6h, then with vacuum freeze drier 48h, (vacuum freeze drier is set
Technological parameter is -40 DEG C, 1.2Pa) powdered (moisture content≤0.1%) is dried into, obtain beans taro leaf ethanol extract.
Experiment one, effect of the beans taro leaf ethanol extract to HepG2 cells
The HepG2 cells of culture are inoculated in 96 orifice plates, per 5000, hole cell, are placed in 37 DEG C, 5%CO2In incubator
It is grouped at random after being incubated 24h, i.e. blank control group, 5,10,20,40,80,160,320,640,1280ug/mL beans taro leaf ethanol
Extract group, every group of hole of repetition 8, is placed in 37 DEG C, 5%CO2After being incubated 24h jointly in incubator, residual liquid in hole is suctioned out, is used
Phosphate buffer (PBS) solution rinses twice.Then (0.5mg/mL is dissolved in without serum free culture system every hole addition 100ul MTT
Base), in 37 DEG C, 5%CO2Continue culture 4 hours in incubator.Then, remove per boreliquid, 100ul dimethyl is added per hole
Sulfoxide (DMSO), shaken 10 minutes on horizontal shaker, ELIASA determines its light absorption value at 570nm.
Cell-proliferation activity (%)=experimental port OD values/control wells OD values * 100%
According to Fig. 1, MTT experiment result is shown, when beans taro leaf ethanol extract concentration is in 0-1280ug/mL, place
Reason is after 24 hours, cell viability no significant difference compared with control group, shows to extract for beans taro leaf ethanol in 0-640ug/mL
Thing safe concentration.
The intracellular fat depositions of HepG2 induced after experiment two, beans taro leaf ethanol extract effect 24h oleic acid (OA)
Influence
The HepG2 cells of culture are inoculated in 6 orifice plates, per hole 4*105Individual cell, it is placed in 37 DEG C, 5%CO2Incubated in incubator
Be grouped at random after educating 24h, i.e., control group (DMEM high glucose medium cellar cultures cell), model group (oleic acid final concentration 0.5mM),
Positive controls (oleic acid final concentration 0.5mM+10uM Bezafibrates), beans taro leaf ethanol extract treatment group (oleic acid final concentration
0.5mM+ final concentration 100ug/mL, 200ug/mL, 300ug/mL beans taro leaves ethanol extract), every group is in triplicate, each group cell
Continue to absorb nutrient solution after cultivating 24h, PBS is softly washed 3 times, and the paraformaldehyde that 500ul 4% is separately added into per hole is fixed carefully
Born of the same parents, stand 20min.PBS softly washs cell 3 times, and 0.5% oil red O stain 30min is added per hole.PBS washings cell 3 times,
Observation is taken pictures under inverted microscope, and 500ul isopropanols are added per hole, and room temperature shaker extracts 200ul extracts after extracting 15 minutes
Light absorption value is determined at 510nm.
It can be seen from Fig. 2, compared with control group, oleic acid, which is handled, causes intracellular fat drips quantity and size substantially to increase, and adds
Enter after Bezafibrate acts on 24h with the beans taro leaf ethanol extract of various concentrations compared with oleic acid induction group, each equal energy for the treatment of group
Significantly reduce intracellular fat drips quantity and size content.Quantitative result is as shown in figure 3, quantitative analysis results again show that beans taro leaf
Ethanol extract shows to significantly reduce liver cell fat deposition effect.
The influence of HepG2 intracellular triglycerides (TG) content that experiment three, beans taro leaf ethanol extract are induced oleic acid
The HepG2 cells of culture are inoculated in 6 orifice plates, per hole 4*105Individual cell, it is placed in 37 DEG C, 5%CO2Incubated in incubator
Be grouped at random after educating 24h, i.e., control group (DMEM high glucose medium cellar cultures cell), model group (oleic acid final concentration 0.5mM),
Positive controls (oleic acid final concentration 0.5mM+10uM Bezafibrates), beans taro leaf ethanol extract treatment group (oleic acid final concentration
0.5mM+ final concentrations 100ug/mL, 200ug/mL, 300ug/mL beans taro leaf ethanol extract), every group is in triplicate, each group cell
Continue cultivate 24h after harvesting, cell pyrolysis liquid is taken after ultrasonication, according to triglycerides (TG enzyme process) testing cassete (Nanjing
Build up Bioengineering Research Institute) method measure intracellular triglyceride content.
It can be seen from Fig. 4, compared with control group, oleic acid, which is handled, causes intracellular triglyceride content significantly to raise, and adds
After the beans taro leaf ethanol extract effect 24h of Bezafibrate and various concentrations compared with oleic acid induction group, each treatment group can show
Writing reduces intracellular triglyceride (TG) content, and beans taro leaf ethanol extract shows to significantly reduce liver cell lipidosis work
With.
The influence of the intracellular T-CHOLs of HepG2 (TC) content that experiment four, beans taro leaf ethanol extract are induced oleic acid
The HepG2 cells of culture are inoculated in 6 orifice plates, per hole 4*105Individual cell, it is placed in 37 DEG C, 5%CO2Incubated in incubator
Be grouped at random after educating 24h, i.e., control group (DMEM high glucose medium cellar cultures cell), model group (oleic acid final concentration 0.5mM),
Positive controls (oleic acid final concentration 0.5mM+10uM Bezafibrates), beans taro leaf ethanol extract treatment group (oleic acid final concentration
0.5mM+ final concentrations 100ug/mL, 200ug/mL, 300ug/mL beans taro leaf ethanol extract), every group is in triplicate, each group cell
Continue cultivate 24h after harvesting, cell pyrolysis liquid is taken after ultrasonication, according to T-CHOL (TCH enzyme process) testing cassete (Nanjing
Build up Bioengineering Research Institute) the intracellular total cholesterol level of method measure.
It can be seen from Fig. 5, compared with control group, oleic acid, which is handled, causes intracellular total cholesterol level significantly to raise, and adds
After the beans taro leaf ethanol extract effect 24h of Bezafibrate and various concentrations compared with oleic acid induction group, each treatment group can show
Writing reduces intracellular T-CHOL (TC) content, and beans taro leaf ethanol extract shows to significantly reduce liver cell lipidosis work
With.
Comparative example 1-1, make " 85% ethanol of 0.1mol/L hydrochloric acid " in the step 1) of embodiment 1 into " 0.1mol/L salt
The straight alcohol of acid ", remaining is equal to embodiment 1.
Comparative example 1-2,85% ethanol by the 0.1mol/L hydrochloric acid in the step 1) of embodiment 1 " makes " 0.1mol/L hydrochloric acid into
70% ethanol ", remaining is equal to embodiment 1.
Comparative example 2-1, the eluant, eluent in the step 3) of embodiment 1 made into by " methanol aqueous solution containing 0.05% formic acid "
" methanol aqueous solution (methanol aqueous solution of volumetric concentration 90%) "；Remaining is equal to embodiment 1.
Comparative example 2-2, the eluant, eluent in the step 3) of embodiment 1 made into by " methanol aqueous solution containing 0.05% formic acid "
" methanol aqueous solution (methanol aqueous solution of volumetric concentration 90%) containing 0.1% formic acid "；Remaining is equal to embodiment 1.
In comparative example 3-1, the step 3) of embodiment 1 as eluant, eluent " 90% methanol containing 0.05% formic acid is water-soluble
Liquid ", make the volumetric concentration of methanol aqueous solution into 80% by 90%；Remaining is equal to embodiment 1.
In comparative example 3-2, the step 3) of embodiment 1 as eluant, eluent " 90% methanol containing 0.0.5% formic acid is water-soluble
Liquid ", make the volumetric concentration of methanol aqueous solution into 100% (that is, pure methanol) by 90%；Remaining is equal to embodiment 1.
Comparative example 4, macroreticular resin is made into macroporous absorbent resin D-101 by macroreticular resin AB-8, remaining is equal to implementation
Example 1.
By the beans taro leaf ethanol extract obtained by above-mentioned all comparative examples according to above-mentioned experiment one~methods described of experiment four
Checked, acquired results are as shown in table 1 below.
Table 1
Finally, it is also necessary to it is noted that listed above is only several specific embodiments of the invention.Obviously, this hair
It is bright to be not limited to above example, there can also be many deformations.One of ordinary skill in the art can be from present disclosure
All deformations for directly exporting or associating, are considered as protection scope of the present invention.
Claims (6)
1. application of the beans taro leaf ethanol extract in liver cell lipidosis is reduced.
2. application of the beans taro leaf ethanol extract according to claim 1 in liver cell lipidosis is reduced, its feature
It is：Medicine, the health food of NASH are treated or prevented for preparing.
3. application of the beans taro leaf ethanol extract according to claim 1 or 2 in liver cell lipidosis is reduced, it is special
Sign is：The preparation method of beans taro leaf ethanol extract is to comprise the following steps：
1), according to 1g:5~10ml solid-liquid ratio is beaten after 85% ethanol of beans taro leaf and the hydrochloric acid containing 0.1mol/L is mixed, institute
Slurries are obtained after 45 ± 5 DEG C of 240 ± 10min of ultrasound extraction, extract solution centrifugation, obtain supernatant；
2) supernatant, is subjected to rotary evaporation concentration until being the 5~10% of original volume in Rotary Evaporators；
3), the concentrate obtained by step 2) is isolated and purified using macroreticular resin；Made with the aqueous formic acid of volumetric concentration 1%
For eluent, the methanol aqueous solution to contain 0.05% formic acid collects eluent as eluant, eluent；
The preparation method of the methanol aqueous solution containing 0.05% formic acid is：In the methanol aqueous solution of 100ml volumetric concentrations 90%
Middle addition 0.05ml formic acid；
4) the eluent rotary evaporation obtained by step 3), is condensed into the 5~10% of most original volume, obtains pulpous state concentrate；
5), then will with vacuum freeze drier, by prior to -70~-90 DEG C 5~7h of pre-freeze of the pulpous state concentrate obtained by step 4)
It is dried to powdered, obtains beans taro leaf ethanol extract.
4. application of the beans taro leaf ethanol extract according to claim 3 in liver cell lipidosis is reduced, its feature
It is：Step 3) is：
Macroreticular resin is activated with the methanol of twice of column volume first, the distilled water of three times column volume is balanced；Then with 0.4~
0.6mL/min flow velocity loading, after liquid to be extracted is fully adsorbed, enter by the use of the aqueous formic acid of volumetric concentration 1% as eluent
Row elution, the dosage of the eluent is twice of column volume, and flow velocity is 0.4~0.6mL/min；Finally use and contain 0.05% formic acid
Methanol aqueous solution eluted as eluant, eluent, the dosage three times column volume of the eluant, eluent, flow velocity is 0.4~0.6mL/
min；Collect eluent.
5. application of the beans taro leaf ethanol extract according to claim 4 in liver cell lipidosis is reduced, its feature
It is：
Macroreticular resin in the step 3) is macroreticular resin AB-8.
6. according to application of any described beans taro leaf ethanol extract of claim 3~5 in liver cell lipidosis is reduced,
It is characterized in that：
By the filter residue alternative steps 1 of step 1) centrifugation gained) in beans taro leaf repeat being beaten of step 1), ultrasound extraction and
Centrifugation；Number of repetition is 2~3 times；
Step 2) is carried out after supernatant obtained by all centrifugations is merged.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711177284.1A CN107812032B (en) | 2017-11-22 | 2017-11-22 | Application of soybean taro leaf ethanol extract in reducing liver cell lipid deposition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711177284.1A CN107812032B (en) | 2017-11-22 | 2017-11-22 | Application of soybean taro leaf ethanol extract in reducing liver cell lipid deposition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107812032A true CN107812032A (en) | 2018-03-20 |
| CN107812032B CN107812032B (en) | 2021-01-26 |
Family
ID=61609852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711177284.1A Active CN107812032B (en) | 2017-11-22 | 2017-11-22 | Application of soybean taro leaf ethanol extract in reducing liver cell lipid deposition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107812032B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040917A (en) * | 2012-12-26 | 2013-04-17 | 浙江农林大学 | Method for preparing total saponins and polysaccharides from Apios americana flowers simultaneously, and application of total saponins and polysaccharides |
-
2017
- 2017-11-22 CN CN201711177284.1A patent/CN107812032B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040917A (en) * | 2012-12-26 | 2013-04-17 | 浙江农林大学 | Method for preparing total saponins and polysaccharides from Apios americana flowers simultaneously, and application of total saponins and polysaccharides |
Non-Patent Citations (8)
| Title |
|---|
| 傅超美: "《中药药剂学》", 31 August 2014, 中国医药科技出版社 * |
| 孔令仪: "《中药制药化学》", 30 April 2007, 中国医药科技出版社 * |
| 安家炜等: "美国豆芋地上部位有效成分及α-葡萄糖苷酶抑制活性研究", 《核农学报》 * |
| 川崎 雅志: ""ラットの血漿および肝臓脂質レベルに対する食餌アピオスの作用", 《BULLETIN OF MORIOKA JUNIOR COLLEGE IWATE PREFECTURAL UNIVERSITY》 * |
| 戚利潮: "美国豆芋不同部位生化特征成分分析", 《浙江农业科学》 * |
| 李晓斐: "《临床常见肝病诊疗进展》", 31 July 2015, 西安交通大学出版社 * |
| 杜方麓: "《中药化学》", 30 June 2006, 中国中医药出版社 * |
| 王燕等: "非酒精性脂肪性肝病分子机制研究进展", 《胃肠病学》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107812032B (en) | 2021-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106236801A (en) | Pseudo-ginseng activity medicine that super-micro wall-broken crushing technology is made and health product and preparation method thereof | |
| CN105963514A (en) | Traditional Chinese medicine product for treating diabetes and preparation method | |
| CN102114102B (en) | Traditional Chinese medicine extract mixed preparation and application thereof | |
| CN105477045A (en) | Traditional Chinese medicine composition containing chrysanthemum and wild chrysanthemum volatile oil and preparation method of traditional Chinese medicine composition | |
| CN107412721A (en) | A kind of hypoglycemic bitter gourd polypeptide compound capsule and preparation method thereof | |
| CN105535112A (en) | Extraction technology of hypoglycemic medicinal active substances of mulberry leaves and mulberries and formula | |
| CN107582562A (en) | Application of the beans taro polysaccharide in liver cell lipidosis is reduced | |
| CN107823247A (en) | Application of the beans taro stem tuber ethanol extract in liver cell lipidosis is reduced | |
| CN107854522A (en) | A kind of composition and its production and use | |
| CN108785370A (en) | A kind of pharmaceutical composition for treating hyperlipemia and atherosclerosis | |
| CN104491048B (en) | A kind of loquat leaf total sesquiterpene glucoside extract and preparation method and application | |
| CN107812032A (en) | Application of the beans taro leaf ethanol extract in liver cell lipidosis is reduced | |
| CN104857245A (en) | Preparation method and application of total saponins from flos hosta ventricosa | |
| CN104771595B (en) | A kind of Chinese medicine composition of strengthen immunity and preparation method thereof | |
| CN107582607A (en) | Application of the beans taro ethanol extract in liver cell lipidosis is reduced | |
| CN102048874B (en) | General flavone extractive of immature bitter orange or bitter orange extracted through water decoction and use of general flavone extractive | |
| CN107823245A (en) | Application of the beans taro leaf water extract in liver cell lipidosis is reduced | |
| CN107582609A (en) | Application of the beans taro water extract in liver cell lipidosis is reduced | |
| CN107951901A (en) | Application of the beans taro leaf polyose in liver cell lipidosis is reduced | |
| CN109381607A (en) | A kind of pharmaceutical composition and its preparation process treated blood disease and merge bacterium infection | |
| CN108379335A (en) | The weight-reducing purposes of beans taro leaf ethanol extract | |
| CN107582606A (en) | The preparation method and its antioxidation application of beans taro ethanol extract | |
| CN107897267A (en) | A kind of health-care moon cake and preparation method thereof | |
| CN102319273A (en) | Salicornia biggelowii Torr. active total saponin extract, its preparation method and its purpose of losing weight | |
| CN106177035A (en) | There is blood sugar lowering, the preparation method and application of anticancer Flos Rosae Chinensis effective extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |